Substrate-selective COX-2 inhibition as a novel strategy for therapeutic endocannabinoid augmentation

Trends in Pharmacological Sciences

Volumn 35, Issue 7, 2014, Pages 358-367

  Hermanson, Daniel J ^a   Gamble George, Joyonna C ^a   Marnett, Lawrence J ^a   Patel, Sachin ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 ARACHIDONOYLGLYCEROL; ACYLGLYCEROL LIPASE; ANANDAMIDE; ANXIOLYTIC AGENT; ARACHIDONIC ACID; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; ENDOCANNABINOID; FATTY ACID AMIDASE; LM 4131; PROSTAGLANDIN; UNCLASSIFIED DRUG;

ANXIETY DISORDER; CARDIOTOXICITY; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; COGNITIVE DEFECT; DRUG SAFETY; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME CONFORMATION; ENZYME INACTIVATION; ENZYME INHIBITION; ENZYME LOCALIZATION; ENZYME SUBSTRATE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HUMAN; IN VIVO STUDY; MAJOR DEPRESSION; METABOLIC DISORDER; METABOLIC REGULATION; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; NEUROTOXICITY; NONHUMAN; OXYGENATION; PRIORITY JOURNAL; PSYCHOPATHY; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; CANNABINOIDS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; HUMANS; SIGNAL TRANSDUCTION; SUBSTRATE SPECIFICITY;

EID: 84903384432     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2014.04.006     Document Type: Review

References (125)

1. M. Kano et al. Endocannabinoid-mediated control of synaptic transmission Physiol. Rev. 89 2009 309 380
2. R. Mechoulam, and L.A. Parker The endocannabinoid system and the brain Annu. Rev. Psychol. 64 2013 21 47
3. K. Ahn et al. Enzymatic pathways that regulate endocannabinoid signaling in the nervous system Chem. Rev. 108 2008 1687 1707 (Pubitemid 351796405)
4. D. Piomelli The molecular logic of endocannabinoid signalling Nat. Rev. Neurosci. 4 2003 873 884 (Pubitemid 37351427)
5. V. Di Marzo Endocannabinoids: synthesis and degradation Rev. Physiol. Biochem. Pharmacol. 160 2008 1 24
6. S. Petrosino, and V. Di Marzo FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels Curr. Opin. Investig. Drugs 11 2010 51 62
7. D. Piomelli The endocannabinoid system: a drug discovery perspective Curr. Opin. Investig. Drugs 6 2005 672 679 (Pubitemid 40904037)
8. J.L. Blankman, and B.F. Cravatt Chemical probes of endocannabinoid metabolism Pharmacol. Rev. 65 2013 849 871
9. B.F. Cravatt et al. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase Proc. Natl. Acad. Sci. U.S.A. 98 2001 9371 9376 (Pubitemid 32743923)
10. S. Kathuria et al. Modulation of anxiety through blockade of anandamide hydrolysis Nat. Med. 9 2003 76 81 (Pubitemid 36098263)
11. I.A. Khasabova et al. Peroxisome proliferator-activated receptor alpha mediates acute effects of palmitoylethanolamide on sensory neurons J. Neurosci. 32 2012 12735 12743
12. J. Fu et al. Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha Nature 425 2003 90 93 (Pubitemid 37101723)
13. S.E. O'Sullivan, and D.A. Kendall Cannabinoid activation of peroxisome proliferator-activated receptors: potential for modulation of inflammatory disease Immunobiology 215 2010 611 616
14. T.P. Dinh et al. Brain monoglyceride lipase participating in endocannabinoid inactivation Proc. Natl. Acad. Sci. U.S.A. 99 2002 10819 10824
15. M.N. Hill et al. The therapeutic potential of the endocannabinoid system for the development of a novel class of antidepressants Trends Pharmacol. Sci. 30 2009 484 493
16. B.P. Roques et al. Inhibiting the breakdown of endogenous opioids and cannabinoids to alleviate pain Nat. Rev. Drug Discov. 11 2012 292 310
17. M.M. Mulvihill, and D.K. Nomura Therapeutic potential of monoacylglycerol lipase inhibitors Life Sci. 92 2013 492 497
18. M. Bari et al. New insights into endocannabinoid degradation and its therapeutic potential Mini Rev. Med. Chem. 6 2006 257 268
19. T. Kosaka et al. Characterization of the human gene (PTGS2) encoding prostaglandin-endoperoxide synthase 2 Eur. J. Biochem. 221 1994 889 897 (Pubitemid 24146188)
20. I. Morita et al. Different intracellular locations for prostaglandin endoperoxide H synthase-1 and -2 J. Biol. Chem. 270 1995 10902 10908
21. M.K. Regier et al. Localization of prostaglandin endoperoxide synthase-1 to the endoplasmic reticulum and nuclear envelope is independent of its C-terminal tetrapeptide-PTEL Arch. Biochem. Biophys. 317 1995 457 463
22. D. Picot et al. The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1 Nature 367 1994 243 249 (Pubitemid 24051139)
23. R. Dietz et al. Higher oxidation states of prostaglandin H synthase. Rapid electronic spectroscopy detected two spectral intermediates during the peroxidase reaction with prostaglandin G2 Eur. J. Biochem. 171 1988 321 328 (Pubitemid 18042896)
24. C.A. Rouzer, and L.J. Marnett Mechanism of free radical oxygenation of polyunsaturated fatty acids by cyclooxygenases Chem. Rev. 103 2003 2239 2304
25. W.A. van der Donk et al. The cyclooxygenase reaction mechanism Biochemistry 41 2002 15451 15458
26. U.R. Mbonye et al. The 19-amino acid cassette of cyclooxygenase-2 mediates entry of the protein into the endoplasmic reticulum-associated degradation system J. Biol. Chem. 281 2006 35770 35778 (Pubitemid 46041308)
27. G. Wu et al. A mechanistic study of self-inactivation of the peroxidase activity in prostaglandin H synthase-1 J. Biol. Chem. 274 1999 9231 9237
28. W.E. Kaufmann et al. COX-2, a synaptically induced enzyme, is expressed by excitatory neurons at postsynaptic sites in rat cerebral cortex Proc. Natl. Acad. Sci. U.S.A. 93 1996 2317 2321 (Pubitemid 26104347)
29. R.C. Harris et al. Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction J. Clin. Invest. 94 1994 2504 2510 (Pubitemid 24379628)
30. K. Yoshikawa et al. Preferential localization of prostamide/prostaglandin F synthase in myelin sheaths of the central nervous system Brain Res. 1367 2011 22 32
31. W.L. Smith et al. Cyclooxygenases: structural, cellular, and molecular biology Annu. Rev. Biochem. 69 2000 145 182
32. A.N. Hata, and R.M. Breyer Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation Pharmacol. Ther. 103 2004 147 166 (Pubitemid 39209041)
33. J.R. Vane Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs Nat. New Biol. 231 1971 232 235
34. J.R. Vane et al. Cyclooxygenases 1 and 2 Annu. Rev. Pharmacol. 38 1998 97 120 (Pubitemid 28231490)
35. K.C. Duggan et al. Molecular basis for cyclooxygenase inhibition by the non-steroidal anti-inflammatory drug naproxen J. Biol. Chem. 285 2010 34950 34959
36. R.G. Kurumbail et al. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents Nature 384 1996 644 648
37. S.W. Rowlinson et al. A novel mechanism of cyclooxygenase-2 inhibition involving interactions with Ser-530 and Tyr-385 J. Biol. Chem. 278 2003 45763 45769 (Pubitemid 37432720)
38. M.A. Windsor et al. Exploring the molecular determinants of substrate-selective inhibition of cyclooxygenase-2 by lumiracoxib Bioorg. Med. Chem. Lett. 23 2013 5860 5864
39. M. Yu et al. Synthesis of prostaglandin E2 ethanolamide from anandamide by cyclooxygenase-2 J. Biol. Chem. 272 1997 21181 21186 (Pubitemid 27373979)
40. K.R. Kozak et al. Oxygenation of the endocannabinoid, 2-arachidonylglycerol, to glyceryl prostaglandins by cyclooxygenase-2 J. Biol. Chem. 275 2000 33744 33749
41. K.R. Kozak et al. Metabolism of the endocannabinoids, 2-arachidonylglycerol and anandamide, into prostaglandin, thromboxane, and prostacyclin glycerol esters and ethanolamides J. Biol. Chem. 277 2002 44877 44885 (Pubitemid 36159083)
42. A. Weber et al. Formation of prostamides from anandamide in FAAH knockout mice analyzed by HPLC with tandem mass spectrometry J. Lipid Res. 45 2004 757 763 (Pubitemid 38405683)
43. K.C. Duggan et al. (R)-Profens are substrate-selective inhibitors of endocannabinoid oxygenation by COX-2 Nat. Chem. Biol. 7 2011 803 809
44. J.K. Ritter et al. Production and actions of the anandamide metabolite prostamide E2 in the renal medulla J. Pharmacol. Exp. Ther. 342 2012 770 779
45. L. Gatta et al. Discovery of prostamide F2alpha and its role in inflammatory pain and dorsal horn nociceptive neuron hyperexcitability PLoS ONE 7 2012 e31111
46. C. Silvestri et al. Anandamide-derived prostamide F2alpha negatively regulates adipogenesis J. Biol. Chem. 288 2013 23307 23321
47. S.S. Hu et al. Prostaglandin E2 glycerol ester, an endogenous COX-2 metabolite of 2-arachidonoylglycerol, induces hyperalgesia and modulates NFkappaB activity Br. J. Pharmacol. 153 2008 1538 1549 (Pubitemid 351481525)
48. P.J. Kingsley et al. Simultaneous analysis of prostaglandin glyceryl esters and prostaglandins by electrospray tandem mass spectrometry Anal. Biochem. 343 2005 203 211 (Pubitemid 41074032)
49. C.A. Rouzer et al. Zymosan-induced glycerylprostaglandin and prostaglandin synthesis in resident peritoneal macrophages: roles of cyclo-oxygenase-1 and -2 Biochem. J. 399 2006 91 99 (Pubitemid 44505410)
50. C.A. Rouzer, and L.J. Marnett Glycerylprostaglandin synthesis by resident peritoneal macrophages in response to a zymosan stimulus J. Biol. Chem. 280 2005 26690 26700 (Pubitemid 41040701)
51. M. Alhouayek et al. Implication of the anti-inflammatory bioactive lipid prostaglandin D2-glycerol ester in the control of macrophage activation and inflammation by ABHD6 Proc. Natl. Acad. Sci. U.S.A. 110 2013 17558 17563
52. K.R. Kozak et al. Metabolism of prostaglandin glycerol esters and prostaglandin ethanolamides in vitro and in vivo J. Biol. Chem. 276 2001 36993 36998
53. S. Xie et al. Inactivation of lipid glyceryl ester metabolism in human THP1 monocytes/macrophages by activated organophosphorus insecticides: role of carboxylesterases 1 and 2 Chem. Res. Toxicol. 23 2010 1890 1904
54. R. Wang et al. Identification of palmitoyl protein thioesterase 1 in human THP1 monocytes and macrophages and characterization of unique biochemical activities for this enzyme Biochemistry 52 2013 7559 7574
55. D.F. Woodward et al. Recent progress in prostaglandin F2alpha ethanolamide (prostamide F2alpha) research and therapeutics Pharmacol. Rev. 65 2013 1135 1147
56. J.J. Prusakiewicz et al. Differential sensitivity and mechanism of inhibition of COX-2 oxygenation of arachidonic acid and 2-arachidonoylglycerol by ibuprofen and mefenamic acid Biochemistry 48 2009 7353 7355
57. D.J. Hermanson et al. Substrate-selective COX-2 inhibition decreases anxiety via endocannabinoid activation Nat. Neurosci. 16 2013 1291 1298
58. A.J. Vecchio, and M.G. Malkowski The structural basis of endocannabinoid oxygenation by cyclooxygenase-2 J. Biol. Chem. 286 2011 20736 20745
59. M.A. Windsor et al. Substrate-selective inhibition of cyclooxygenase-2: development and evaluation of achiral profen probes ACS Med. Chem. Lett. 3 2012 759 763
60. D.D. Leipold et al. Bioinversion of R-flurbiprofen to S-flurbiprofen at various dose levels in rat, mouse, and monkey Chirality 16 2004 379 387 (Pubitemid 38833318)
61. J. Kim, and B.E. Alger Inhibition of cyclooxygenase-2 potentiates retrograde endocannabinoid effects in hippocampus Nat. Neurosci. 7 2004 697 698 (Pubitemid 38859050)
62. H. Yang et al. COX-2 oxidative metabolism of endocannabinoids augments hippocampal synaptic plasticity Mol. Cell. Neurosci. 37 2008 682 695
63. A. Straiker et al. COX-2 and fatty acid amide hydrolase can regulate the time course of depolarization-induced suppression of excitation Br. J. Pharmacol. 164 2011 1672 1683
64. W.R. Marrs et al. The serine hydrolase ABHD6 controls the accumulation and efficacy of 2-AG at cannabinoid receptors Nat. Neurosci. 13 2010 951 957
65. S.G. Kinsey et al. Inhibition of endocannabinoid catabolic enzymes elicits anxiolytic-like effects in the marble burying assay Pharmacol. Biochem. Behav. 98 2010 21 27
66. A. Busquets-Garcia et al. Differential role of anandamide and 2-arachidonoylglycerol in memory and anxiety-like responses Biol. Psychiatry 70 2011 479 486
67. N.R. Sciolino et al. Enhancement of endocannabinoid signaling with JZL184, an inhibitor of the 2-arachidonoylglycerol hydrolyzing enzyme monoacylglycerol lipase, produces anxiolytic effects under conditions of high environmental aversiveness in rats Pharmacol. Res. 64 2011 226 234
68. F.A. Moreira et al. Reduced anxiety-like behaviour induced by genetic and pharmacological inhibition of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) is mediated by CB1 receptors Neuropharmacology 54 2008 141 150 (Pubitemid 350299416)
69. S. Patel, and C.J. Hillard Pharmacological evaluation of cannabinoid receptor ligands in a mouse model of anxiety: further evidence for an anxiolytic role for endogenous cannabinoid signaling J. Pharmacol. Exp. Ther. 318 2006 304 311
70. B. Kumari et al. Protective effect of non-selective and selective COX-2-inhibitors in acute immobilization stress-induced behavioral and biochemical alterations Pharmacol. Rep. 59 2007 699 707 (Pubitemid 351586561)
71. A. Dhir et al. Protective effect of naproxen (non-selective COX-inhibitor) or rofecoxib (selective COX-2 inhibitor) on immobilization stress-induced behavioral and biochemical alterations in mice Eur. J. Pharmacol. 535 2006 192 198
72. S. Akhondzadeh, and S. Jafari A double-blind, placebo-controlled trial of celecoxib adjunctive treatment to fluoxetine in major depression Br. J. Clin. Pharmacol. 70 2010 291 292
73. S. Akhondzadeh et al. Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial Depress. Anxiety 26 2009 607 611
74. N. Muller et al. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine Mol. Psychiatry 11 2006 680 684 (Pubitemid 43989814)
75. D.J. Hermanson, and L.J. Marnett Cannabinoids, endocannabinoids, and cancer Cancer Metastasis Rev. 30 2011 599 612
76. N. Futaki et al. NS-398, a novel non-steroidal anti-inflammatory drug with potent analgesic and antipyretic effects, which causes minimal stomach lesions Gen. Pharmacol. 24 1993 105 110 (Pubitemid 23089182)
77. G. Engelhardt et al. Anti-inflammatory, analgesic, antipyretic and related properties of meloxicam, a new non-steroidal anti-inflammatory agent with favourable gastrointestinal tolerance Inflamm. Res. 44 1995 423 433
78. M.A. Crilly, and A.A. Mangoni Non-steroidal anti-inflammatory drug (NSAID) related inhibition of aldosterone glucuronidation and arterial dysfunction in patients with rheumatoid arthritis: a cross-sectional clinical study BMJ Open 1 2011 e000076
79. T.M. Macdonald et al. Methodology of a large prospective, randomised, open, blinded endpoint streamlined safety study of celecoxib versus traditional non-steroidal anti-inflammatory drugs in patients with osteoarthritis or rheumatoid arthritis: protocol of the standard care versus celecoxib outcome trial (SCOT) BMJ Open 3 2013 e002295
80. M. Dougados et al. Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug Arthritis Rheum. 44 2001 180 185 (Pubitemid 32113133)
81. E. Scopelitis, and H. Mcgrath NSAID-masked gout South. Med. J. 80 1987 1464 1465 (Pubitemid 18003272)
82. L.J. Marnett, and R.N. DuBois COX-2: a target for colon cancer prevention Annu. Rev. Pharmacol. Toxicol. 42 2002 55 80 (Pubitemid 34160519)
83. M. Retsky et al. Reduction of breast cancer relapses with perioperative non-steroidal anti-inflammatory drugs: new findings and a review Curr. Med. Chem. 20 2013 4163 4176
84. M. Wagner et al. COX-2 expression and effects of selective inhibition in prostate cancer cell lines J. Urol. 167 2002 135 136
85. J.D. Kelly, and E. Hall Boxing bladder cancer with COX-2-specific inhibition Cancer Prev. Res. 4 2011 1534 1535
86. D.P. Eisen Manifold beneficial effects of acetyl salicylic acid and nonsteroidal anti-inflammatory drugs on sepsis Intens. Care Med. 38 2012 1249 1257
87. M.J. Stables et al. Priming innate immune responses to infection by cyclooxygenase inhibition kills antibiotic-susceptible and -resistant bacteria Blood 116 2010 2950 2959
88. C. Patrono Molecular and clinical determinants of the cardiovascular effects of selective COX-isozyme inhibition Ann. Rheum. Dis. 64 2005 39 40
89. G.A. Fitzgerald Coxibs and cardiovascular disease N. Engl. J. Med. 351 2004 1709 1711
90. J.A. Mitchell, and T.D. Warner COX isoforms in the cardiovascular system: understanding the activities of non-steroidal anti-inflammatory drugs Nat. Rev. Drug Discov. 5 2006 75 85
91. C.P. Cannon, and P.J. Cannon COX-2 inhibitors and cardiovascular risk Science 336 2012 1386 1387
92. Y. Yu et al. Vascular COX-2 modulates blood pressure and thrombosis in mice Sci. Transl. Med. 4 2012 132ra154
93. T.D. Warner, and J.A. Mitchell COX-2 selectivity alone does not define the cardiovascular risks associated with non-steroidal anti-inflammatory drugs Lancet 371 2008 270 273
94. G.K. Wilcock Disease-modifying treatments for Alzheimer's disease: a perspective based on experience with R-Flurbiprofen Alzheimers Dement. 2 2006 150 152 (Pubitemid 43843096)
95. G.K. Wilcock et al. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial Lancet Neurol. 7 2008 483 493
96. J.L. Goldstein et al. Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor Am. J. Gastroenterol. 95 2000 1681 1690 (Pubitemid 30485002)
97. J.C. Becker et al. Current approaches to prevent NSAID-induced gastropathy - COX selectivity and beyond Br. J. Clin. Pharmacol. 58 2004 587 600 (Pubitemid 39665146)
98. J.Z. Long et al. Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in vivo Proc. Natl. Acad. Sci. U.S.A. 106 2009 20270 20275
99. J. Liu et al. Hepatic cannabinoid receptor-1 mediates diet-induced insulin resistance via inhibition of insulin signaling and clearance in mice Gastroenterology 142 2012 1218-1228
100. R. Cinar et al. Hepatic cannabinoid-1 receptors mediate diet-induced insulin resistance by increasing de novo synthesis of long-chain ceramides Hepatology 59 2014 143 153
101. J. Liu et al. Monounsaturated fatty acids generated via stearoyl CoA desaturase-1 are endogenous inhibitors of fatty acid amide hydrolase Proc. Natl. Acad. Sci. U.S.A. 110 2013 18832 18837
102. V. Di Marzo, and L. De Petrocellis Why do cannabinoid receptors have more than one endogenous ligand? Philos. Trans. R. Soc. Lond. B: Biol. Sci. 367 2012 3216 3228
103. L. Cristino et al. Immunohistochemical localization of anabolic and catabolic enzymes for anandamide and other putative endovanilloids in the hippocampus and cerebellar cortex of the mouse brain Neuroscience 151 2008 955 968
104. K.A. Slanina, and P. Schweitzer Inhibition of cyclooxygenase-2 elicits a CB1-mediated decrease of excitatory transmission in rat CA1 hippocampus Neuropharmacology 49 2005 653 659 (Pubitemid 41208287)
105. C.J. Fowler et al. Ibuprofen inhibits the metabolism of the endogenous cannabimimetic agent anandamide Pharmacol. Toxicol. 80 1997 103 107 (Pubitemid 27078234)
106. S.T. Glaser, and M. Kaczocha Cyclooxygenase-2 mediates anandamide metabolism in the mouse brain J. Pharmacol. Exp. Ther. 335 2010 380 388
107. J.R. Ghilardi et al. Constitutive spinal cyclooxygenase-2 participates in the initiation of tissue injury-induced hyperalgesia J. Neurosci. 24 2004 2727 2732 (Pubitemid 38380949)
108. H. Guhring et al. A role for endocannabinoids in indomethacin-induced spinal antinociception Eur. J. Pharmacol. 454 2002 153 163 (Pubitemid 35287474)
109. L.E. Staniaszek et al. Effects of COX-2 inhibition on spinal nociception: the role of endocannabinoids Br. J. Pharmacol. 160 2010 669 676
110. J. Guindon et al. Synergistic antinociceptive effects of anandamide, an endocannabinoid, and nonsteroidal anti-inflammatory drugs in peripheral tissue: a role for endogenous fatty-acid ethanolamides? Eur. J. Pharmacol. 550 2006 68 77 (Pubitemid 44572265)
111. J. Guindon et al. Local interactions between anandamide, an endocannabinoid, and ibuprofen, a nonsteroidal anti-inflammatory drug, in acute and inflammatory pain Pain 121 2006 85 93 (Pubitemid 43261635)
112. A. Telleria-Diaz et al. Spinal antinociceptive effects of cyclooxygenase inhibition during inflammation: involvement of prostaglandins and endocannabinoids Pain 148 2010 26 35
113. I. Matias et al. Prostaglandin ethanolamides (prostamides): in vitro pharmacology and metabolism J. Pharmacol. Exp. Ther. 309 2004 745 757 (Pubitemid 38542631)
114. C.S. Nirodi et al. The glyceryl ester of prostaglandin E2 mobilizes calcium and activates signal transduction in RAW264.7 cells Proc. Natl. Acad. Sci. U.S.A. 101 2004 1840 1845 (Pubitemid 38228978)
115. R.A. Ross et al. Pharmacological characterization of the anandamide cyclooxygenase metabolite: prostaglandin E2 ethanolamide J. Pharmacol. Exp. Ther. 301 2002 900 907 (Pubitemid 34595078)
116. Y. Liang et al. Identification and pharmacological characterization of the prostaglandin FP receptor and FP receptor variant complexes Br. J. Pharmacol. 154 2008 1079 1093 (Pubitemid 351915050)
117. R. Richie-Jannetta et al. Structural determinants for calcium mobilization by prostaglandin E2 and prostaglandin F2alpha glyceryl esters in RAW 264.7 cells and H1819 cells Prostaglandins Other Lipid Mediat. 92 2010 19 24
118. N. Sang et al. COX-2 oxidative metabolite of endocannabinoid 2-AG enhances excitatory glutamatergic synaptic transmission and induces neurotoxicity J. Neurochem. 102 2007 1966 1977 (Pubitemid 47329266)
119. S. Valdeolivas et al. The inhibition of 2-arachidonoyl-glycerol (2-AG) biosynthesis, rather than enhancing striatal damage, protects striatal neurons from malonate-induced death: a potential role of cyclooxygenase-2-dependent metabolism of 2-AG Cell Death Dis. 4 2013 e862
120. D.F. Woodward et al. Bimatoprost: a novel antiglaucoma agent Cardiovasc. Drug Rev. 22 2004 103 120 (Pubitemid 38879875)
121. N. Sang et al. PGE2 glycerol ester, a COX-2 oxidative metabolite of 2-arachidonoyl glycerol, modulates inhibitory synaptic transmission in mouse hippocampal neurons J. Physiol. 572 2006 735 745
122. L. Dong et al. Human cyclooxygenase-2 is a sequence homodimer that functions as a conformational heterodimer J. Biol. Chem. 286 2011 19035 19046
123. R.J. Kulmacz, and W.E.M. Lands Prostaglandin-H synthase - stoichiometry of heme cofactor J. Biol. Chem. 259 1984 6358 6363 (Pubitemid 14108180)
124. C. Yuan et al. Cyclooxygenase allosterism, fatty acid-mediated cross-talk between monomers of cyclooxygenase homodimers J. Biol. Chem. 284 2009 10046 10055
125. R.J. Kulmacz, and W.E. Lands Stoichiometry and kinetics of the interaction of prostaglandin H synthase with anti-inflammatory agents J. Biol. Chem. 260 1985 12572 12578 (Pubitemid 16233460)